COMPASS Pathways (NASDAQ:CMPS) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

COMPASS Pathways (NASDAQ:CMPS) issued its quarterly earnings data on Thursday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS traded up $0.22 during mid-day trading on Thursday, reaching $3.92. 1,179,233 shares of the company’s stock were exchanged, compared to its average volume of 1,273,669. The firm has a market capitalization of $268.21 million, a price-to-earnings ratio of -1.78 and a beta of 2.28. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.75. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The firm has a 50-day moving average price of $4.06 and a two-hundred day moving average price of $5.29.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday. They issued a “buy” rating and a $11.00 target price on the stock. HC Wainwright decreased their price objective on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Maxim Group decreased their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $27.33.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.